P.5.a.005 Effect of cholinesterase inhibitors on cholinergic deficit induced by 3-quinuclidinyl benzilate in rats performing the multiple T-maze

2013 ◽  
Vol 23 ◽  
pp. S537-S538
Author(s):  
J. Misik ◽  
J. Kassa ◽  
A. Kracmarova
Keyword(s):  
Cholinesterase Inhibitors ◽  
Cholinergic Deficit ◽  
Quinuclidinyl Benzilate

scholarly journals Testing Van Gool’s Hypothesis: A Method to Predict Side Effects of Cholinesterase Inhibitors in Patients with Cellular Degenerative and Vascular Dementia

2015 ◽  
Vol 2015 ◽  
pp. 1-6
Author(s):  
Liza van Eijk ◽  
Erwin R. Groot ◽  
Maritza van Spronsen ◽  
Yvonne J. Maas ◽  
Daniel Keeser ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Side Effects ◽  
Vascular Dementia ◽  
Sustained Attention ◽  
Cholinergic System ◽  
Cholinesterase Inhibitors ◽  
Medical Outcome ◽  
Attention Task ◽  
Cholinergic Deficit ◽  
Different Doses

This study investigates a method to predict medical outcome of cholinesterase inhibitors in patients with Alzheimer’s disease (AD) and vascular dementia (VaD). Van Gool predicts that patients with cholinergic deficit symptoms will benefit from treatment whereas patients without will experience side effects because of overstimulation of the cholinergic system. We predicted that AD and VaD patients with a longer RT experience fewer side effects than patients with a faster response and that VaD patients have a longer RT than AD patients. A number of 71 patients with AD or VaD diagnosis were included. A sustained attention task was administered, as well as the MMSE and a questionnaire about side effects. Results indicated that VaD patients with a longer RT reported fewer side effects. Furthermore, patients with VaD had a longer RT than patients with AD. MMSE was negatively correlated with RT in the VaD group. Thus, the performance on the attention task seems associated with suffering from side effects and thus tends to predict medical outcome in VaD, but not in AD. Perhaps this attention task was not sensitive enough to measure cholinergic deficit symptoms in AD patients. Furthermore, different doses of medication might confound the effect for the AD group.

Assessing Cholinesterase Inhibitors

2007 ◽  
Vol 40 (18) ◽  
pp. 8-9
Author(s):  
THOMAS FINUCANE
Keyword(s):  
Cholinesterase Inhibitors

Dementia with Lewy bodies

2018 ◽  
pp. 11-21
Author(s):  
O. S. Levin ◽  
E. E. Vasenina ◽  
A. Sh. Chimagomedova ◽  
N. G. Dudchenko
Keyword(s):  
Parkinson’S Disease ◽  
Dementia With Lewy Bodies ◽  
Cholinesterase Inhibitors ◽  
Lewy Bodies ◽  
Diagnosis And Treatment ◽  
Modern Concept ◽  
Historical Aspect ◽  
Neurodegenerative Process ◽  
Icd 10

Te lecture presents modern concept of the symptoms, diagnosis and treatment of dementia with Lewy bodies (DLB), which accounts for about 10% of cases of dementia. Te nosological status of DLB and the problem of ratio of DLB and Parkinson’s disease which, apparently, represent two phenotypic variants of one neurodegenerative process («diseases with Lewy bodies») are considered in historical aspect. Approaches to the diagnosis and coding of DLB in accordance with ICD-10 are proposed. Te role of cholinesterase inhibitors, antipsychotics, levodopa, rasagiline and other drugs in the treatment of patients with DLB is аnalyzed.

Rationale for the Development of Cholinesterase Inhibitors as Anti- Alzheimer Agents

2004 ◽  
Vol 10 (25) ◽  
pp. 3111-3119 ◽  
Author(s):  
D. Lahiri ◽  
J. Rogers ◽  
N. Greig ◽  
K. Sambamurti
Keyword(s):  
Cholinesterase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document